In a victory for President Barack Obama, the Democratic-controlled House narrowly passed landmark health care legislation
Saturday night to expand coverage to tens of millions who lack it and place tough new restrictions on the insurance industry. The 220-215 vote cleared the way for the Senate to begin a long-delayed debate
on the issue that has come to overshadow all others in Congress.
At this point in the health reform debate, you have to take numbers from any side with a grain of salt. That said, Indianapolis-based
WellPoint Inc. has done perhaps the only local analysis of how proposed reforms would affect the cost of health insurance
for employers.
After winning 83-percent support for $754 million hospital, Wishard officials hope to sell bonds, pick construction firm
by year’s end.
IUPUI political scientist Bill Blomquist predicts the Wishard hospital referendum will pass by a "comfortable"
margin.
Tuesday’s vote will determine if Marion County Health & Hospital Corp. can sell up to $703 million in taxpayer-backed bonds
to replace the county-owned hospital.
Biotechnology behemoth Amgen Inc. is being sued by 15 states, including Indiana, alleging the company gave kickbacks to medical
providers to help boost sales of the Aranesp.
The health care overhaul bill produced by House Democrats would impose an array of new taxes, fees and government mandates
on major players in the health industry, including drug companies and big medical-device makers headquartered in Indiana.
After no Indiana health and life sciences firms announced venture capital deals in the second quarter, five did so in the
third, and two more have already this month.
The big goal of health care reform is to cut wasteful spending to pay for expanded health insurance coverage. But the way
the Senate Finance Committee bill tries to do that would be, according to some doctors, “disastrous.”
Some Indianapolis-area doctors fear a bill in the U.S. Senate would botch the way costs for tests and procedures are calculated, and ultimately
lead to a reimbursement system that works worse than the existing system.
The Indianapolis Chamber of Commerce is throwing its weight behind a tougher workplace smoking ban up for consideration tonight
by the City-County Council.
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Wishard Memorial Hospital in Indianapolis closed its main operating rooms and canceled at least 15 surgeries Friday after
a steam pipe burst. Hospital officials say the burst pipe is an example of the infrastructure problems that are prompting
plans for a new facility.
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
You know, there’s an election on Nov. 3, right? We’re not voting for president, governor,
mayor, or even dog catcher. We’re voting for a critical piece of the health care delivery system in central Indiana: whether to allow Marion County
Health & Hospital Corp. to sell bonds to build a new Wishard Hospital.
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Goodwill Industries executive Keith Reissaus has been tapped to run Washington, D.C.-based Leapfrog Group, an industry coalition.
Reissaus gained control of health care costs by giving employees incentives to care about their health.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
